We are live on
!
Find out more
E Fund Management Portfolio holdings
AUM
$4.46B
Turnover
13.19%
This Fund
S&P 500
This Quarter
Est. Return
+11.44%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$194M
(+12%)
Cap. Flow
+$40.5M
Cap. Flow
% of AUM
2.24%
Top 10 Holdings %
Top 10 Hldgs %
63.7%
Holding
392
New
24
Increased
176
Reduced
102
Closed
74
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Futu Holdings
FUTU
|
+$32.5M |
| 2 |
Applied Materials
AMAT
|
+$26.5M |
| 3 |
Apple
AAPL
|
+$13.7M |
| 4 |
Microsoft
MSFT
|
+$11.9M |
| 5 |
NVIDIA
NVDA
|
+$9.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$28.3M |
| 2 |
KE Holdings
BEKE
|
+$13.2M |
| 3 |
TSMC
TSM
|
+$13.2M |
| 4 |
ASE Group
ASX
|
+$7.59M |
| 5 |
iQIYI
IQ
|
+$6.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 39.73% |
| 2 | Technology | 31.74% |
| 3 | Communication Services | 9.52% |
| 4 | Healthcare | 5.08% |
| 5 | Financials | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
Dyne Therapeutics
DYN
$2.68B
| $312K | 0.02% |
8,829
-7,446
| -46% | -$216K |
2024 Q1
1 quarter
|
|
227
Twist Bioscience
TWST
$8.74B
| $309K | 0.02% |
6,261
-5,274
| -46% | -$215K |
2022 Q1
9 quarters
|
|
228
NetApp
NTAP
$40.2B
| $308K | 0.02% |
+2,391
| New | +$268K |
2024 Q2
0 quarters
|
|
229
DELISTED
Crinetics Pharmaceuticals
CRNX
| $305K | 0.02% |
6,813
-3,435
| -34% | -$159K |
2023 Q3
3 quarters
|
|
230
CoStar Group
CSGP
$12.8B
| $304K | 0.02% |
4,095
+76
| +2% | +$6.44K |
2022 Q4
6 quarters
|
|
231
Acadia Pharmaceuticals
ACAD
$3.31B
| $301K | 0.02% |
18,528
+40
| +0.2% | +$646 |
2022 Q1
9 quarters
|
|
232
Bristol-Myers Squibb
BMY
$124B
| $299K | 0.02% |
7,190
+840
| +13% | +$37.6K |
2021 Q1
13 quarters
|
|
233
Xcel Energy
XEL
$47.4B
| $298K | 0.02% |
5,585
+106
| +2% | +$5.77K |
2021 Q1
13 quarters
|
|
234
DELISTED
Nuvalent
NUVL
| $298K | 0.02% |
3,929
-1,207
| -24% | -$85.9K |
2023 Q3
3 quarters
|
|
235
Zoetis
ZTS
$32.6B
| $293K | 0.02% |
1,689
+24
| +1% | +$3.99K |
2021 Q1
13 quarters
|
|
236
Ardelyx
ARDX
$808M
| $289K | 0.02% |
39,033
-10,835
| -22% | -$76.2K |
2023 Q1
5 quarters
|
|
237
DELISTED
Arcellx
ACLX
| $288K | 0.02% |
5,212
-774
| -13% | -$42.1K |
2023 Q1
5 quarters
|
|
238
Western Digital
WDC
$127B
| $287K | 0.02% |
+5,005
| New | +$278K |
2024 Q2
0 quarters
|
|
239
Coca-Cola Europacific Partners
CCEP
$49.1B
| $286K | 0.02% |
3,922
+101
| +3% | +$7.27K |
2023 Q4
2 quarters
|
|
240
McKesson
MCK
$117B
| $284K | 0.02% |
487
-51
| -9% | -$28.4K |
2023 Q4
2 quarters
|
|
241
Intellia Therapeutics
NTLA
$1.53B
| $283K | 0.02% |
12,665
-1,795
| -12% | -$42.7K |
2022 Q1
9 quarters
|
|
242
CVS Health
CVS
$118B
| $279K | 0.02% |
4,722
+467
| +11% | +$29.2K |
2021 Q1
13 quarters
|
|
243
First Solar
FSLR
$18.7B
| $278K | 0.02% |
+1,232
| New | +$269K |
2024 Q2
0 quarters
|
|
244
DELISTED
Amicus Therapeutics
FOLD
| $275K | 0.02% |
27,734
-7,498
| -21% | -$77K |
2021 Q1
13 quarters
|
|
245
Keysight
KEYS
$57.3B
| $274K | 0.02% |
2,001
+572
| +40% | +$83.6K |
2021 Q1
13 quarters
|
|
246
Becton Dickinson
BDX
$52B
| $272K | 0.02% |
1,165
-12
| -1% | -$2.83K |
2021 Q1
13 quarters
|
|
|
RNAM
247
DELISTED
Avidity Biosciences
RNAM
| $271K | 0.02% |
6,640
-2,857
| -30% | -$82K |
2022 Q4
6 quarters
|
|
248
Celldex Therapeutics
CLDX
$2.19B
| $269K | 0.01% |
7,258
-1,788
| -20% | -$67.5K |
2022 Q1
9 quarters
|
|
249
Teradyne
TER
$52.2B
| $268K | 0.01% |
+1,809
| New | +$230K |
2024 Q2
0 quarters
|
|
250
Vera Therapeutics
VERA
$2B
| $268K | 0.01% |
7,395
-865
| -10% | -$34.3K |
2024 Q1
1 quarter
|
|
Similar funds
E Fund Management's Q2 2024 Portfolio in Review
As of Q2 2024, E Fund Management held 392 positions worth $1.81B, up 12% from $1.61B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
E Fund Management's Q2 2024 filing shows 24 new, 176 increased, 102 reduced and 74 closed positions. Its largest new stake was Futu Holdings: 480,000 shares worth $31.5M. The largest sale was Advanced Micro Devices, an estimated $28.3M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.
- E Fund Management's largest Q2 2024 buy was Futu Holdings: 480,000 shares worth $31.5M.
- E Fund Management added most to Applied Materials in Q2 2024, an estimated $26.5M increase.
- E Fund Management's biggest Q2 2024 reduction was Advanced Micro Devices, cutting an estimated $28.3M.
- E Fund Management fully exited Yum China in Q2 2024, selling an estimated $5.17M.
- E Fund Management's ten largest holdings make up 64% of its $1.81B portfolio in Q2 2024.
- E Fund Management opened 24 new positions and closed 74 in Q2 2024.
- E Fund Management's portfolio value rose 12% quarter-over-quarter to $1.81B.
Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.